Last week, a decision was made in Israel that most people probably did not notice. It did not make front-page headlines. It was not debated on television. Yet for a small and devastated community of families in Israel and around the world, it was the news we had been waiting years to hear.

IWILFIN, a maintenance therapy for high-risk neuroblastoma, has been approved for inclusion in Israel’s national health basket.

IWILFIN is used as a maintenance therapy intended to help reduce the risk of relapse and protect the progress children have fought so hard to achieve. Because neuroblastoma relapse is still tragically common, giving children every possible chance to stay in remission is not optional; it is essential.

Advocating for IWILFIN’s inclusion in Israel’s health basket became one of our central goals. The therapy has been approved by major regulators and represents an important additional option for children in remission. For years, Israeli families watched as access to the medication expanded elsewhere while remaining largely out of reach here. That reality has now changed, and it matters enormously.

The approval of IWILFIN proves that progress is possible. It is a reminder that advocacy matters, that voices matter, and that change can happen when people refuse to accept delay as inevitable.